Teva Pharmaceutical Industries Limited (TEVA)

Market Cap	47.89B +106.6%
Revenue (ttm)	17.32B +4.1%
Net Income	706.00M
EPS	0.60
Shares Out	1.17B
PE Ratio	68.31
Forward PE	14.58
Dividend	n/a
Ex-Dividend Date	n/a

Volume	14,822,347
Open	40.22
Previous Close	39.25
Day's Range	40.12 - 42.02
52-Week Range	18.83 - 42.02
Beta	0.82
Analysts	Buy
Price Target	45.27 (+10.15%)
Earnings Date	Nov 3, 2026

About TEVA

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The com...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1901
• Employees: 33,950
• Stock Exchange: NYSE
• Ticker Symbol: TEVA
• Website: https://www.tevapharm.com

Analyst Summary

According to 12 analysts, the average rating for TEVA stock is "Buy." The 12-month stock price target is $45.27, which is an increase of 10.15% from the latest price.

Price Target

$45.27

(10.15% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Oct 10, 2026

Data Sources Report a data error